JMP Securities maintains Enanta stock with $21 target
JMP Securities reiterated a Market Outperform rating on Enanta Pharmaceuticals (NASDAQ:ENTA) shares with a consistent price target of $21.00. The firm's analysis highlighted the company's solid ...
JMP Securities Sticks to Their Buy Rating for KalVista Pharmaceuticals (KALV)
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price ...
JMP reiterates AtriCure stock with $60 target, sees growth
JMP Securities maintained its optimistic stance on AtriCure Inc. (NASDAQ:ATRC), reiterating a Market Outperform rating and a $60.00 price target. The firm's analysts highlighted their anticipation for ...
JMP Securities Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)
JMP Securities analyst Reni Benjamin maintained a Buy rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of ...
JMP Securities Raises Axon Enterprise, Inc. (AXON) Price Target to $725 on AI & Defense Demand
As the US stock markets were catching up with the tech disruption led by cheap Chinese AI models, US President Donald Trump’s ...
KBC Group NV Boosts Stake in Sabra Health Care REIT, Inc. (NASDAQ:SBRA)
KBC Group NV increased its holdings in Sabra Health Care REIT, Inc. (NASDAQ:SBRA – Free Report) by 66.2% in the fourth ...